Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Teniposide facilitates macrophage phagocytosis by targeting the CD47-SIRPα axis and the candidate protein TRIM54 in lung cancer.

Created on 19 Aug 2026

Authors

Ning Han, Long Nie, Liu-Gen Li, Xing-Chun Peng, Lei Wang, Si-Yuan Chen, Jun Hu, Fan Leng, Hongyao Huang, Tong-Fei Li, Xiao Chen

Published in

Biochimica et biophysica acta. Molecular basis of disease. Pages 168429. Aug 18, 2026. Epub Aug 18, 2026.

Abstract

The precise inhibition of CD47-SIRPα interaction to promote macrophage phagocytosis and thereby mobilize the immune microenvironment is an essential strategy in lung cancer immunotherapy. Herein, we explored the role of Teniposide (Ten/VM-26) in the CD47-SIRPα interactions and macrophage phagocytosis, with insights into the target and molecular mechanism. Ten/VM-26 demonstrated not only chemotherapeutic but also immunostimulatory effects in lung cancer models. Macrophage depletion attenuated the immune activation induced by Ten, which was associated with enhanced phagocytosis, cGAS-STING signaling, and M1 polarization of macrophages. Our data indicated that Ten suppressed CD47 and thereby dampened the interaction between CD47 and SIRPα, which are highly expressed in lung cancer cells and macrophages respectively. Conversely, CD47 supplementation impaired Ten-driven phagocytosis and M1 polarization of macrophages. Further data suggested that Ten bound to TRIM54, which may be involved in CD47 ubiquitination and degradation. To summarize, our findings suggest that Ten down-regulates CD47 through its binding to both CD47 and TRIM54, thereby disrupting the CD47-SIRPα interaction, enhancing macrophage phagocytosis, cGAS-STING activation, and promoting M1 polarization, supporting the potential of targeting CD47 for lung cancer immunotherapy.

PMID:
42612756
Bibliographic data and abstract were imported from PubMed on 19 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 13
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement